Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
← catalyst calendarNCT07503405 · readout ≤ 102 d
Sponsored by Traws Pharma, Inc. (industry) · TRAW — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
165estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2026 | estimated | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Influenza
Interventions
- Drug: TRX-100
- Drug: Placebo
- Biological: Influenza A/France/759/2021 (H1N1) virus
Primary outcomes
what the primary-completion date above is the date OFLaboratory-Confirmed Infection
measured From Day 1 (pm) up to Day 8 (am)
Symptoms of Grade ≥2
measured From Day 1 (am) to Day 8 (am)
Permalink · TRAW's whole pipeline · Catalyst calendar · Every registered study · What changed